Five Ventures Taps Biotech Cos

Close to half of the company semi-finalists in the annual Five Ventures interactive business plan competition are biotechnology companies.

UNC Charlotte's Charlotte Research Institute, which is host of the competition, expanded the categories for this year's competition to include medical devices as well as traditional drug discovery.

"The expansion of the biotech category into pharma and device categories is indicative of where North Carolina is as a whole," said Barry Burks, Ph.D., the associate director of CRI.

"While innovation in Pharma remains strong, our dividing the life science category to showcase devices also demonstrates that the pipeline of biotech innovation is large and our robust biomedical device cluster continues to expand.”

The presenting companies by category are:

Biotechnology - pharmaceutical category

  • Alaeras
  • Cell Guard
  • Countervail
  • Inhibikase Therapeutics
  • Oncologen

Biotechnology - device category

  • Entogenetics
  • HepatoSys
  • Ligmar
  • Microscopy Research Innovations
  • and Restorative Physiology Group

These semi-finalists make a presentation to a selection committee. Ten of the 25 semi-finalists will become finalists and receive coaching for a final presentation at the Five Ventures Competition on April 9.

For more information visit www.FiveVentures.com

Tue, 03/17/2009 - 04:00